Minoryx spins off asset into new Swiss company

Spain-based Minoryx Therapeutics s.l. has spun out a platform technology into a new company, enabling it to focus on its lead programme MIN-102 for the treatment of X-linked adrenoleukodystrophy, a genetic disorder affecting the nervous system.

Full text available to subscribers only. Click here for information on subscribing to MedNous.